NIH-funded research R01 grant

Enhancing newborn screening to better treat Krabbe, Pompe, and MPS I

Official title: Enhancement of Newborn Screening Diagnostic Paradigms to Improve the Efficacy of Treatment for Krabbe Disease, Pompe Disease, and Mucopolysaccharidosis Type 1

Funded at State University of New York at Buffalo · NIH-11387708 · Data updated 2026-11-12

A study to improve how newborns are screened for Krabbe disease, Pompe disease, and MPS I so that babies who need treatment are identified faster and more accurately.

More Newborn research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionState University of New York at Buffalo
NIH-funded
Lab location1 site (Amherst, United States)
Project startMarch 18, 2022
Project endFebruary 28, 2027
Funding year2026
Award (this year)$616,228
NIH project number5R01HD104814-05
Project IDNIH-11387708 on NIH RePORTER

Who could benefit from this research

Could help

Newborns who undergo routine screening and are being evaluated for KD, PD, or MPS I.

Less likely to help

Infants who are not identified by the BVNL method may not experience a change in their screening outcomes.

What this research studies

This project aims to refine the diagnostic approach used in newborn screening by focusing on two biomarkers in dried blood spots to reduce false positives and speed up correct diagnoses. It builds on prior work showing that combining psychosine levels with an enzyme marker can predict symptoms before they appear, potentially leading to earlier and more effective treatment. The study will evaluate and optimize the BVNL (two-biomarker) method in a larger newborn population to improve positive predictive value and reduce unnecessary interventions. Parents and clinicians could benefit from clearer results, fewer anxious false positives, and quicker access to therapy when needed.

Why it matters

Potential benefit: If successful, babies with KD, PD, or MPS I could start treatment sooner with fewer unnecessary procedures and less parental anxiety.

How similar studies have gone: Prior work showed a high PPV (98.5%) for the BVNL approach in KD, suggesting promising potential in expanding accuracy across the three diseases.

Where this research is happening

  • State University of New York at Buffalo
    Amherst, United States
    Active

Researchers

  • Principal investigator: Woo, Daniel — State University of New York at Buffalo
  • Study coordinator: Woo, Daniel

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.